Skip to main content

Advertisement

SpringerLink
Log in

Patient practices in hidradenitis suppurativa flare management: a cross-sectional survey study

  • RESEARCH LETTER
  • Published:
Archives of Dermatological Research Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. LeWitt TM, Mammis-Gierbolini A, Parnell M et al (2022) International consensus definition of disease flare in hidradenitis suppurativa. Br J Dermatol 187(5):785–787. https://doi.org/10.1111/bjd.21647

    Article  PubMed  PubMed Central  Google Scholar 

  2. Alikhan A, Sayed C, Alavi A et al (2019) North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations: part II: topical, intralesional, and systemic medical management. J Am Acad Dermatol 81(1):91–101. https://doi.org/10.1016/j.jaad.2019.02.068

    Article  PubMed  PubMed Central  Google Scholar 

  3. Savage KT, Singh V, Patel ZS et al (2021) Pain management in hidradenitis suppurativa and a proposed treatment algorithm. J Am Acad Dermatol 85(1):187–199. https://doi.org/10.1016/j.jaad.2020.09.039

    Article  PubMed  Google Scholar 

  4. Thompson AM, Fernandez JM, Shih T, Hamzavi I, Hsiao JL, Shi VY (2022) Improving hidradenitis suppurativa patient education using written action plan: a randomized controlled trial. J Dermatol Treat 33(5):2677–2679. https://doi.org/10.1080/09546634.2021.1970707

    Article  Google Scholar 

  5. Price KN, Thompson AM, Rizvi O et al (2020) Complementary and alternative medicine use in patients with hidradenitis suppurativa. JAMA Dermatol 156(3):345–348. https://doi.org/10.1001/jamadermatol.2019.4595

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Funding

This study has no funding source.

Author information

Author notes

  1. Sarah E. Park and Rahul Masson: contributed equally.

Authors and Affiliations

  1. David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA

    Sarah E. Park

  2. Keck School of Medicine of USC, University of Southern California, Los Angeles, CA, USA

    Rahul Masson

  3. Kaiser Permanente Los Angeles Medical Center, Los Angeles, CA, USA

    Terri Shih

  4. Department of Dermatology, University of Arkansas for Medical Sciences, Little Rock, AR, USA

    Vivian Y. Shi

  5. Department of Dermatology, University of Southern California, Los Angeles, CA, USA

    Jennifer L. Hsiao

  6. Department of Dermatology, Stanford University School of Medicine, Redwood City, CA, USA

    Maria A. Aleshin

Authors
  1. Sarah E. Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rahul Masson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Terri Shih
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Vivian Y. Shi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jennifer L. Hsiao
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Maria A. Aleshin
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

SP and RM wrote the main manuscript text and prepared the figure/table. TS performed comparative statistics. All authors reviewed the manuscript.

Corresponding author

Correspondence to Maria A. Aleshin.

Ethics declarations

Conflict of interest

VYS is on the board of directors for the Hidradenitis Suppurativa Foundation (HSF), an advisor for the National Eczema Association, is a stock shareholder of Learn Health and has served as an advisory board member, investigator, speaker, and/or received research funding from Sanofi Genzyme, Regeneron, AbbVie, Genentech, Eli Lilly, Novartis, SUN Pharma, LEO Pharma, Pfizer, Incyte, Boehringer Ingelheim, Alumis Aristea Therapeutics, Menlo Therapeutics, Dermira, Burt’s Bees, Galderma, Kiniksa, UCB, Target-PharmaSolutions, Altus Lab/cQuell, MYOR, Polyfins Technology, GpSkin and Skin Actives Scientific. JLH is on the board of directors for the Hidradenitis Suppurativa Foundation, has served as a consultant for Aclaris, AbbVie, Boehringer Ingelheim, Incyte, Novartis, and UCB; as a speaker for AbbVie; as an investigator for Amgen, Boehringer Ingelheim, and Incyte. MA has served as a consultant for AbbVie, Novartis, Santa Ana Bio and has received research funding from UCB. All other authors report no conflicts of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Park, S.E., Masson, R., Shih, T. et al. Patient practices in hidradenitis suppurativa flare management: a cross-sectional survey study. Arch Dermatol Res 316, 13 (2024). https://doi.org/10.1007/s00403-023-02782-4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s00403-023-02782-4

Keywords

Search

Navigation